EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

BACH2: The Future of Induced T-Regulatory Cell Therapies

Daniel Zwick, Mai Tram Vo, Young Jun Shim iD, Helena Reijonen, Jeong-Su Do iD

Cells · 2024

DOI: 10.3390/cells13110891 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Daniel Zwick und 4 weiteren Autor:innen. Beteiligte Einrichtung: Frederick National Laboratory, Frederick, MD 21701, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Basic-Leucine Zipper Transcription Factors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Margie & Robert Petersen Foundation, Margie & Robert Petersen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACH2 (BTB Domain and CNC Homolog 2) is a transcription factor that serves as a central regulator of immune cell differentiation and function, particularly in T and B lymphocytes. A picture is emerging that BACH2 may function as a master regulator of cell fate that is exquisitely sensitive to cell activation status. In particular, BACH2 plays a key role in stabilizing the phenotype and suppressive function of transforming growth factor-beta (TGF-β)-derived human forkhead box protein P3 (FOXP3)+ inducible regulatory T cells (iTregs), a cell type that holds great clinical potential as a cell therapeutic for diverse inflammatory conditions. As such, BACH2 potentially could be targeted to overcome the instability of the iTreg phenotype and suppressive function that has hampered their clinical application. In this review, we focus on the role of BACH2 in T cell fate and iTreg function and stability. We suggest approaches to modulate BACH2 function that may lead to more stable and efficacious Treg cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryBasic-Leucine Zipper Transcription FactorsHumansAnimalsForkhead Transcription FactorsCell- and Tissue-Based TherapyCell Differentiation

Stichwörter der Autor:innen

BACH2FOXP3 stabilityT lymphocytesinducible regulatory T cells

Substanzen

Basic-Leucine Zipper Transcription FactorsBACH2 protein, humanForkhead Transcription Factors

Autor:innen und Institutionen

  • Frederick National Laboratory, Frederick, MD 21701, USA.
  • School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Department of Immunology and Theranostics, City of Hope, Duarte, CA 91010, USA.

ORCID-Profile: Young Jun Shim, Jeong-Su Do

Förderung

  • Margie & Robert Petersen Foundation
  • Margie & Robert Petersen Foundation

Zitieren

APA

Zwick, D., Vo, M. T., Shim, Y. J., Reijonen, H., & Do, J. S. (2024). BACH2: The Future of Induced T-Regulatory Cell Therapies. Cells. https://doi.org/10.3390/cells13110891

Vancouver

Zwick D, Vo MT, Shim YJ, Reijonen H, Do JS. BACH2: The Future of Induced T-Regulatory Cell Therapies. Cells. 2024. doi:10.3390/cells13110891

BibTeX
@article{Zwick2024,
  author = {Zwick, Daniel and Vo, Mai Tram and Shim, Young Jun and Reijonen, Helena and Do, Jeong-Su},
  title = {BACH2: The Future of Induced T-Regulatory Cell Therapies},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13110891}
}
Kostenlos starten →